会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • RIBOSOMAL PROTEIN S6 AS A PHARMACODYNAMIC MARKER FOR HSP90 INHIBITION
    • 核糖体蛋白S6作为HSP90抑制药物动力学标记物
    • WO2007090032A3
    • 2007-11-01
    • PCT/US2007061060
    • 2007-01-25
    • SERENEX INCOTTO JAMES CRANDELL JRFADDEN PATRICKRICE JOHN
    • OTTO JAMES CRANDELL JRFADDEN PATRICKRICE JOHN
    • G01N33/50
    • G01N33/5011
    • The present invention provides methods for identifying inhibitors of heat shock protein 90 (Hsp90), for identifying clinical conditions responsive to Hsp90 inhibitors, and for monitoring clinical efficacy of Hsp90 inhibitors. Methods for identifying Hsp90 inhibitors comprise comparing the level of phosphorylation of ribosomal protein S6 (RPS6) in a sample contacted with a potential Hsp90 inhibitor to the level of phosphorylation of RPS6 in a control sample not exposed to the potential inhibitor. In some embodiments, a test cell is contacted with a putative Hsp90 inhibitor and the level of phosphorylation of RPS6 in the cell is compared to the level of phosphorylation of RPS6 in a control cell not exposed to the putative inhibitor, where a decrease in the level of phosphorylation of RPS6 in the contacted test cell is indicative of inhibition of Hsp90 activity. The invention further provides methods of predicting whether a subject with a tumor or other cellular proliferative disorder will respond to an agent that inhibits Hsp90 activity. Such predictions are based on a comparison of the levels of phosphorylation of RPS6 in test tumor cells or other abnormally proliferating cells contacted with the Hsp90 inhibitor to the level of phosphorylation of RPS6 in control cells not treated with the inhibitor, where a decrease in the level of phosphorylation of RPS6 in the test cells contacted with the Hsp90 inhibitor is predictive of a positive response to the Hsp90 inhibitor. The methods of the invention find use in monitoring clinical efficacy of Hsp90 inhibitors.
    • 本发明提供了用于鉴定热休克蛋白90(Hsp90)的抑制剂,用于鉴定对Hsp90抑制剂有响应的临床病症以及用于监测Hsp90抑制剂的临床功效的方法。 鉴定Hsp90抑制剂的方法包括比较与潜在Hsp90抑制剂接触的样品中核糖体蛋白S6(RPS6)的磷酸化水平与未暴露于潜在抑制剂的对照样品中RPS6的磷酸化水平。 在一些实施方案中,将测试细胞与推定的Hsp90抑制剂接触,并将细胞中RPS6的磷酸化水平与未暴露于推定抑制剂的对照细胞中RPS6的磷酸化水平进行比较,其中水平 接触的测试细胞中RPS6的磷酸化指示Hsp90活性的抑制。 本发明进一步提供了预测患有肿瘤或其他细胞增殖性病症的受试者是否会对抑制Hsp90活性的试剂起反应的方法。 这样的预测是基于RPS6在测试肿瘤细胞或与Hsp90抑制剂接触的其他异常增殖细胞中的磷酸化水平与未用抑制剂处理的对照细胞中RPS6磷酸化水平的比较,其中水平降低 在与Hsp90抑制剂接触的测试细胞中RPS6磷酸化可预测对Hsp90抑制剂的阳性反应。 本发明的方法可用于监测Hsp90抑制剂的临床功效。
    • 8. 发明申请
    • BRACKET AND BRIDGING MEMBER FOR METAL STUD WALL
    • 金属墙壁支架和桥梁构件
    • WO2006084367A3
    • 2006-09-28
    • PCT/CA2006000188
    • 2006-02-13
    • BAILEY METAL PRODUCTS LTDRICE JOHN
    • RICE JOHN
    • E04B2/00E04B1/38E04B2/58E04C5/18
    • E04B2/763E04B2/7457
    • A bracket for use in a metal stud wall having internal bridging members for tying the metal studs and bridging members together. The bracket comprises an L shaped bracket having a leg for overlying the bridging member joined to an upright for overlying the metal stud. The outside corners of the leg and upright of the L shaped bracket are truncated so that the bracket may be inserted within the channel of a metal stud and rotated to the proper position for attaching to the bridging member and metal stud. In an aspect of the invention, the bridging member being provided with openings at regular intervals along its length thereof to aid in spacing of the studs in the metal stud partition wall. The bracket is provided with a downwardly extending tab at the junction of the leg and the upright sized to fit within an opening of the bridging member.
    • 用于金属螺柱壁的支架,其具有用于将金属螺柱和桥接构件捆绑在一起的内部桥接构件。 支架包括一个L形支架,该支架具有用于覆盖桥接构件的腿部,该桥接构件连接到用于覆盖金属支柱的立柱上。 腿部的外角和L形支架的直立部分被截断,使得支架可以插入金属螺柱的通道内并且旋转到适当的位置以附接到桥接构件和金属螺柱。 在本发明的一个方面,桥接构件沿着其长度设置有规则间隔的开口,以有助于螺柱在金属螺柱分隔壁中的间隔。 支架在腿部和立柱的接合部处设置有向下延伸的突出部,其尺寸适于配合在桥接构件的开口内。